Bio­haven claims $300M+ pub­lic of­fer­ing as com­pa­ny charts new jour­ney af­ter Pfiz­er buy­out

Bio­haven re­port­ed its Q3 earn­ings Wednes­day, just a few weeks af­ter Pfiz­er made a ma­jor pur­chase of the com­pa­ny’s CGRP port­fo­lio. And tucked away in the re­port, the biotech not­ed a mas­sive raise.

The biotech re­port­ed that as of Oc­to­ber 25, it closed a pre­vi­ous­ly men­tioned pub­lic of­fer­ing for 28,750,000 shares at $10.50 per share. Un­der­writ­ers had the op­tion to pur­chase an ad­di­tion­al 3,750,000 shares at that same price. The over­all gross pro­ceeds? $301.9 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER